Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

PHASE1

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

DRUG: 2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet
DRUG: 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet
DRUG: 5 mg dapagliflozin / 850 mg metformin XR FDC
DRUG: 5 mg dapagliflozin / 1000 mg metformin XR FDC
DRUG: 2.5 mg ONGLYZA® (saxagliptin) tablet
DRUG: 5 mg Forxiga® (dapagliflozin) tablet
DRUG: 500 mg Glucophage XR®

AstraZeneca